ArticleJAMA2023
Ushering in a New Era of Alzheimer Disease Therapy.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations between adverse pregnancy outcomes and cognitive impairment and dementia: a systematic review and meta-analysis.The lancet. Healthy longevity · 2024Pooled it
- Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry: A Randomized Clinical Trial.JAMA health forum · 2025Trial
- Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.Neurology · 2025Trial
- Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.JAMA neurology · 2025Trial
- Improving the Delivery of Brain Health Care to All. Keeping our Eye on the Main Prize in an Era of Emerging Anti-Amyloid Therapies.Canadian geriatrics journal : CGJ · 2026Article
- Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan.Journal of the American Geriatrics Society · 2025Article
- Perspectives of Patients and Care Partners on Benefits or Burdens of Delaying Dementia Progression.JAMA network open · 2025Article
- N-N-Substituted Piperazine, Cmp2, Improves Cognitive and Motor Functions in 5xFAD Mice.International journal of molecular sciences · 2025Article
- A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment.Journal of Alzheimer's disease : JAD · 2025Article
- Convening Hispanic/Latino Caregiving Advisors for Inclusive Research in Dementia Palliative Care.Journal of palliative medicine · 2025Article
- Harnessing diversity to study Alzheimer's disease: A new iPSC resource from the NIH CARD and ADNI.Neuron · 2024Article
- Talking With Patients About the New Anti-amyloid Alzheimer Disease Medications.Annals of internal medicine · 2024Article
- Alzheimer's disease and its treatment-yesterday, today, and tomorrow.Frontiers in pharmacology · 2024Review
- Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.International journal of molecular sciences · 2023Review
- Uptake and safety profile of anti-amyloid immunotherapies in routine clinical practice.Journal of Alzheimer's disease reportsArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
37459123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.